PSP
8
2
4
1
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 8 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 1 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (8)
AMX0035 and Progressive Supranuclear Palsy
Digital Health Technologies for Progressive Supranuclear Palsy and Dementia With Lewy Bodies
Integrated Management of Atypical Parkinsonism: A Home-based Patient-Centered Healthcare Delivery Based on Telenursing (IMPACT Study)
Intraoperative Bupivacaine Injection to Reduce Acute and Chronic Pain After TVT/TVT-O Surgery. Randomized Double-Blind Trial
A Multi-Modal Remote Monitoring Platform for Frontotemporal Lobar Degeneration (FTLD) Syndromes
The CurePSP Genetics Program
Repetitive Transcranial Magnetic Stimulation in Frontotemporal Lobar Degeneration
Clinico-Pathologic-Genetic-Imaging Study of Neurodegenerative and Related Disorders